CD274 and familial pancreatic carcinoma: To examine the therapeutic effect of the biomimetic nanomedicine on checkpoint inhibitor therapy, we treated the orthotopic pancreatic cancer mice with a combinational regimen of PD-L1 antibody (α-PD-L1) and PG@KMCM (Fig. 5a).